Introduction
============

Tongue cancer is a common cancer in the mouth, accounting for 30--50% of all oral cancers. The most common type of tongue cancer is squamous cell carcinoma. Statistics indicated that the incidence is significantly higher for men compared to women ([@b1-ol-0-0-10271],[@b2-ol-0-0-10271]). As the population in China is aging, the incidence of tongue cancer among elderly people is increasing year by year. Because blood vessels and lymphatic vessels are rich in the tongue and the tongue muscle is frequently squeezed due to structural reasons, tongue squamous cell carcinoma is prone to metastasize even in its early stage and therefore has a poor prognosis ([@b3-ol-0-0-10271],[@b4-ol-0-0-10271]). Early diagnosis and early treatment of tongue squamous cell carcinoma is the key to patient recovery. At present, commonly used clinical treatment options for tongue squamous cell carcinoma are surgery, chemotherapy, radiotherapy and comprehensive treatment. However, therapeutic outcomes of patients with early tongue squamous cell carcinoma using various surgical protocols are still open to debate, and few related studies can be found in literature ([@b5-ol-0-0-10271],[@b6-ol-0-0-10271]). In this study, retrospective analysis was performed on clinical records of 128 patients with early tongue squamous cell carcinoma who were treated in Henan Province Hospital of TCM (Zhengzhou, China) from June, 2010 to June, 2013. Therapeutic outcomes of these patients with early tongue squamous cell carcinoma were compared between three treatment options, i.e. surgical therapy alone, preoperative radiotherapy and postoperative radiotherapy. This study aimed to provide a more precise treatment plan for patients with tongue cancer in different stages and to improve treatment.

Materials and methods
=====================

### Subjects

Clinical records of 128 patients with early tongue squamous cell carcinoma who were treated in Henan Province Hospital of TCM from June, 2010 to June, 2013 were retrospectively analyzed. According to adopted treatment plan, the patients were divided into 3 groups: 92 patients in surgical therapy alone group, 13 patients in preoperative radiotherapy group, and 23 patients in postoperative radiotherapy group.

The study was approved by the Εthics Committee of Henan Province Hospital of TCM. Patients who participated in this research had complete clinical data. The signed informed consents were obtained from the patients or the guardians.

### Inclusion criteria

Patients who met the following criteria were eligible for the study: i) Patients who were diagnosed to have primary tongue squamous cell carcinoma in the early stages (cT1-2N0); ii) patients who received treatment for the first time; iii) patients whose lesion was on the forward portion of the tongue; and iv) patients who had complete clinical records.

### Exclusion criteria

Patients who met the following criteria were excluded from this study: i) patients who also had other kinds of primary cancers; ii) patients who also had lymph node metastasis; iii) patients who underwent cervical lymph node dissection; iv) patients with pathologically positive surgical margins; and v) patients who had a survival of less than two months.

### Treatment procedures

Patients in the surgical therapy alone group underwent primary lesion resection, which was performed by physicians who had been in clinical practice for more than 5 years. The diseased tissue was removed along a cut edge 1--2 cm away from the lesion, resulting in cancer-free resection margins. Patients in the preoperative radiotherapy group received preoperative radiotherapy in addition to the above-mentioned primary lesion resection. First, the lesion location was determined by imaging techniques and the results of clinical diagnosis. Then, radiotherapy was given by external beam radiation alone or combination of external beam radiation and internal radiation by inserting a radiation source inside the tissue (combined radiation). The total dose of external beam radiation therapy was 50--72 Gy (64.5±4.7 Gy), and the energy range of external radiation source was 5--6 MV. The total dose of combined radiation therapy was \<60 Gy. Radiotherapy was completed within 15--70 days before surgery. The radiotherapy protocol in the postoperative radiotherapy group was similar to that in the preoperative radiotherapy group mentioned above. The total dose of external beam radiation therapy was 50--72 Gy (66.1±5.3 Gy), and the total dose of combined radiation therapy was \<70 Gy. Radiotherapy was completed within 15--75 days after surgery.

### Research method

Statistical analysis was performed on patient general data and clinical records, as well as the patient\'s 5-year survival rate and recurrence rate. The general data and clinical records included sex ratio, age distribution, disease course (referring to the time from onset to operation), pathological type, and clinical stage. The statistics of patients\' clinical data were obtained by follow-up. The starting time of follow-up is the discharge time of patients, and the end time was 30 June 2018 or the death of patients. The forms of follow-up mainly include questionnaire, telephone, and outpatient follow-up.

### Statistical analysis

Data were processed using SPSS 19.0 (IBM Corp., Armonk, NY, USA) statistics software. The χ^2^ test was used for comparison of quantitative data which were expressed as (mean ± SD). The t-test was used for comparison of measurement data. Differences in survival rate between groups were obtained by using the Kaplan-Meier test and log rant test. Results of multivariate analysis were obtained by using the COX test. A difference was considered statistically significant at P\<0.05.

Results
=======

### Comparison of patient general data

As shown in [Table I](#tI-ol-0-0-10271){ref-type="table"}, there were no statistically significant differences in sex ratio, age distribution, disease course, pathological type, clinical stage, and tumor location among the three groups.

### Comparison of survival rate

The overall 5-year survival rate for all patients was 86.7% (111/128), that of stage I was 88.5% (62/70), and that of stage II was 84.5% (49/58). The 5-year disease-specific survival rate was 88.8% (111/125), which was 91.2% (62/68) in stage I, and 85.9% (49/57) in stage II. In individual groups, the 5-year survival rate and the 5-year disease-specific survival rate were 91.3% (84/92) and 91.3% (84/92), respectively, in the surgical therapy alone group 76.9% (10/13) and 83.3% (10/12), respectively, in the preoperative radiotherapy group, and 73.9% (17/23) and 81.0% (17/21), respectively, in the postoperative radiotherapy group. There were no statistically significant differences in 5-year survival rate (χ^2^=5.990, P=0.051) and 5-year disease-specific survival rate (χ^2^=2.223, P=0.329) among the three groups. The results are shown in [Figs. 1](#f1-ol-0-0-10271){ref-type="fig"} and [2](#f2-ol-0-0-10271){ref-type="fig"}.

### Comparison of recurrence rate and metastatic rate in the three groups

As shown in [Table II](#tII-ol-0-0-10271){ref-type="table"}, there were 25 cases of recurrence in total during follow-up. The recurrence rate was 19.5%; the local recurrence rate was 11.7% (15/128); and the regional recurrence rate was 7.8% (10/128). There were 5 cases of metastasis, and the metastatic rate was 4.7%. There were no statistically significant differences in recurrence rate and metastatic rate among the three groups.

Discussion
==========

Surgical therapy is the primary treatment option for tongue cancer, while radiotherapy and chemotherapy are adjuvant therapy. Patients rarely receive radiotherapy or chemotherapy alone for tongue cancer. Radiotherapy and chemotherapy have proven systemic toxic side effects, and physicians are unable to reach a consensus on whether they have an impact on patient survival ([@b7-ol-0-0-10271],[@b8-ol-0-0-10271]). All the subjects in this study underwent surgical treatment and included the majority of patients diagnosed with tongue squamous cell carcinoma. This study aimed to provide a scientific reference for the treatment of tongue cancer.

Patients with tongue cancer have a poor prognosis. The 5-year survival rate is about 27% for mid-stage/late stage patients. The subjects included in this study were all patients with early tongue squamous cell carcinoma, for whom few research reports appear in literature. In this study, the overall 5-year survival rate and the 5-year disease-specific survival rate were 86.7 and 88.8%, respectively, which were all higher compared with similar studies in literature ([@b9-ol-0-0-10271],[@b10-ol-0-0-10271]). The causes of this exceptional result could be that i) the patients selected in this study had milder symptoms or ii) continuous advancement of medical technology led to overall improvement of treatment outcomes such as overall survival rate of patients with early tongue squamous cell carcinoma ([@b11-ol-0-0-10271],[@b12-ol-0-0-10271]). There were no statistically significant differences in 5-year survival rate among patients in the three groups. To get more accurate results, a larger sample size may be needed because the number of subjects in this study reached the threshold. However, some studies have pointed out that ([@b13-ol-0-0-10271]) functional and aesthetic deficiencies caused by radical surgery can reduce the quality of life of patients, so conservative treatment is better than radical treatment for elderly patients aged over 60 years. Therefore, the average age of patients selected into this study is lower than 60 years.

The main purpose of preoperative radiotherapy was to attenuate tumor cell activity and reduce the risk of tumor cell implantation into benign lesions, thereby lowering cancer recurrence rate and metastatic rate. In addition, preoperative radiotherapy can significantly decrease tumor cell volume, making the surgical procedures a little easier to perform. The postoperative radiotherapy was to give patients more precise radiotherapy in terms of location and dose because related information can be more accurately obtained after surgery and verified using imaging techniques. Postoperative radiotherapy was expected to improve the treatment ([@b13-ol-0-0-10271],[@b14-ol-0-0-10271]). In this study, it was found that adjuvant radiotherapy did not improve the 5-year survival rate of patients with early tongue cancer. Our finding was opposite to reports in literature ([@b15-ol-0-0-10271],[@b16-ol-0-0-10271]), and the possible reason could be that the recruited patients with early tongue cancer had relatively milder symptoms. Surgery caused great tissue injury to the patient\'s body. In addition, systemic side effects of radiotherapy can seriously affect the immune system. Surgical therapy alone would be enough to achieve the treatment goal. In order to avoid overtreatment and reduce complexity of treatment procedures, the authors suggest that surgical therapy alone be adopted to treat patients with early tongue squamous cell carcinoma.

There were 25 cases of recurrence in total during follow-up. The recurrence rate was 19.5%; the local recurrence rate was 11.7% (15/128); and the regional recurrence rate was 7.8% (10/128). There were 6 cases of metastasis, and the metastatic rate was 4.7%. It was found that neither preoperative radiotherapy nor postoperative radiotherapy can reduce the 5-year recurrence rate. The possible reason could be that both preoperative radiotherapy and postoperative radiotherapy had a balance between effectiveness in killing cancer cells and aggressiveness in causing damage to the body ([@b17-ol-0-0-10271]--[@b19-ol-0-0-10271]). Radiotherapy caused great damage to the patient\'s body, and was probably too aggressive for treating early tongue squamous cell carcinoma. Preoperative and postoperative radiotherapy should be avoided as much as possible.

In conclusion, compared with surgical therapy alone, radiotherapy combined with surgical therapy neither improved 5-year survival rate nor reduced recurrence rate. Therefore, surgical therapy alone is suggested to be the preferred option for treating patients with early tongue squamous cell carcinoma.
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###### 

Comparison of patient general data.

  Variant                       Surgical therapy alone group (n=92)   Preoperative radiotherapy group (n=13)   Postoperative radiotherapy group (n=23)   χ^2^    P-value
  ----------------------------- ------------------------------------- ---------------------------------------- ----------------------------------------- ------- ---------
  Sex                                                                                                                                                            
    Male                        56                                    8                                        15                                        0.146   0.929
    Female                      36                                    5                                          8                                               
  Age (years)                   53.1±6.9                              55.4±7.1                                 54.9±7.3                                  0.663   0.794
  Smoking                                                                                                                                                0.024   0.988
    Yes                         51                                    7                                        13                                                
    No                          41                                    6                                        10                                                
  Disease course                                                                                                                                                 
    \>6 months                  52                                    6                                        11                                        0.903   0.637
    ≤6 months                   40                                    7                                        12                                                
  Pathological type                                                                                                                                              
    Well differentiated         70                                    9                                        16                                        0.470   0.791
    Moderately differentiated   14                                    3                                          5                                               
    Poorly differentiated         8                                   1                                          2                                               
  Clinical stage                                                                                                                                                 
    Stage I                     53                                    8                                          9                                       2.787   0.248
    Stage II                    39                                    5                                        14                                                
  Tumor location                                                                                                                                                 
    Lateral tongue              65                                    9                                        17                                        0.076   0.963
    Ventral tongue              21                                    3                                          4                                               
    Dorsal tongue                 6                                   1                                          2                                               

###### 

Comparison of recurrence rate and metastatic rate in the three groups.

  Variant               Surgical therapy alone group   Preoperative radiotherapy group   Postoperative radiotherapy group   χ^2^    P-value
  --------------------- ------------------------------ --------------------------------- ---------------------------------- ------- ---------
  Patient number        92                             13                                23                                         
  Recurrence            18                               2                                 5                                0.282   0.868
  Local recurrence      11                               1                                 3                                0.225   0.880
  Regional recurrence     7                              1                                 2                                0.087   0.958
  Metastasis              3                              1                                 1                                0.743   0.690
